Related Experiment Video
Updated: Aug 10, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
[Pharmacological treatment resistant schizophrenia]
S Cervera Enguix1, A Seva Fernández
1Clínica Universitaria de Navarra, Universidad de Navarra, Pamplona. s.cervera@unav.es
Actas Espanolas De Psiquiatria
|March 10, 2006
Summary
Identifying treatment resistance in schizophrenia requires careful assessment of patient factors and medication trials. Distinguishing true resistance from other issues ensures appropriate management for antipsychotic non-responders.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Context:
- Schizophrenia treatment presents challenges with patients unresponsive to antipsychotic medications.
- Distinguishing between treatment-resistant, treatment-refractory, and non-respondent schizophrenia is crucial for effective clinical management.
- Established criteria, including Kane's 1988 guidelines and scales like BPRS and ILSS, aid in assessing treatment resistance.
Purpose:
- To clarify the definition and diagnostic considerations for treatment resistance in schizophrenia.
- To outline key factors influencing treatment resistance, such as schizophrenia type, substance abuse, and adherence.
- To provide guidelines for managing antipsychotic medication resistance in schizophrenia.
Summary:
- Treatment resistance in schizophrenia is distinct from chronicity or severity, necessitating evaluation of primary/secondary nature, substance abuse, adherence, and neurological signs.
- Accurate diagnosis involves differentiating resistance from intolerance, non-compliance, or inadequate psychosocial support.
- Effective management includes clear symptom identification, appropriate medication dosage/duration, monotherapy before polytherapy, minimizing extrapyramidal effects, and maintaining a positive therapeutic stance.
Impact:
- Improved diagnostic accuracy for treatment-resistant schizophrenia.
- Enhanced clinical decision-making for optimizing antipsychotic therapy.
- Better patient outcomes through tailored treatment strategies for non-responsive individuals.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...